drugset / Trial / NCT07799493

Caplyta Versus Placebo for Adults With Social Anxiety Disorder

NCT07799493 ↗

Phase 4 Recruiting 40 enrolled Jason Careri
RandomizedParallel-groupTriple-blindTreatment

Summary

The goal of this clinical trial is to learn if Caplyta works to treat Social Anxiety Disorder in adults. The main question it aims to answer is: Does Caplyta lower the frequency/severity of social anxiety symptoms in adults? Researchers will compare Caplyta to a placebo (a look-alike substance that contains no drug) to see if Caplyta works to treat Social Anxiety Disorder. Participants will: Take Caplyta or a placebo every day for 8 weeks Visit the clinic once every week for checkups and tests

Timeline

Start
2026-09-10
Primary completion
2028-05-18
Completion
2028-05-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Lumateperone Small molecule 42 mg —

Indications